[Edaily Reporter YU JIN-HEE ] Amid global interest rate uncertainty and a downturn in biotech investment sentiment, leading domestic pharmaceutical and biotech companies— Yuhan(000100)and HK inno.N Corporation(195940)—have both posted solid results, demonstrating their “fundamental strength.” When adjusted for the quarterly seasonal fluctuations typical of the pharmaceutical industry and compared to the same period last year, both companies continued to show clear growth in operating profit, a key profitability metric.

According to the Financial Supervisory Service’s electronic disclosure system on the 28th, Yuhan Corporation’s preliminary operating profit for the third quarter of this year, on a standalone basis, was 34.748 billion won, a 44.2% surge compared to the same period last year (24.102 billion won). Revenue for the same period reached 585.744 billion won, up 6.3% from the same period last year, demonstrating growth in both scale and profitability.

Year-to-date figures show an even steeper growth trend. Yuhan Corporation’s cumulative revenue from January through September this year reached 1.709394 trillion won, an 8.4% increase compared to the same period last year, while cumulative operating profit surged 34.0% to 105.02 billion won, surpassing the 100 billion won mark in operating profit after just three quarters. On a consolidated basis, cumulative third-quarter revenue and operating profit also reached 1.770541 trillion won and 108.89 billion won, respectively, demonstrating a stable growth trajectory.

HK inno.N Corporation also demonstrated robust financial health centered on profitability. HK inno.N Corporation’s operating profit for the third quarter of this year was 26 billion won, a slight increase of 0.6% year-over-year. While revenue for the same period stood at 260.4 billion won—a slight decrease of 0.2% year-over-year—net income rose 5.6% year-over-year to 19.6 billion won (from 18.6 billion won), successfully maintaining profitability.

HK inno.N Corporation’s cumulative performance from January through September also showed a steep upward trend. While cumulative revenue rose only 1.9% year-over-year to 786.3 billion won, cumulative operating profit surged 26.1% year-over-year to 89.2 billion won. Cumulative net profit for the same period also increased by 23.3% to 59.2 billion won.

An industry insider in the pharmaceutical and biotech sector commented, “Although liquidity for the biotech sector in the capital markets remains limited, traditional pharmaceutical companies like Yuhan and HK inno.N Corporation—which have secured solid cash cows based on their own pipelines and flagship products—are proving their corporate value through their financial performance, achieving double-digit operating profit growth compared to the previous year.”